Obes Res Clin Pract. 2024;18(6):457-464.
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
제1저자 Takashi Kadowaki · 교신저자 Takashi Kadowaki, 임수
소속 (8)
- Toranomon Hospital, Tokyo, Japan. Electronic address: kadowaki@toranomon.kkr.or.jp.
- Family Medicine Clinic and Biomedical Research Institute, Pusan National University Yangsan Hospital, Yangsan, South Korea; Department of Medical Education, Pusan National University School of Medicine, Yangsan, South Korea.
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Novo Nordisk Pharma Ltd., Tokyo, Japan.
- Novo Nordisk A/S, Søborg, Denmark.
- First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, Toyama, Japan.
- Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. Electronic address: limsoo@snu.ac.kr.
Abstract
OBJECTIVE To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.
METHODS In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks. A subset of Japanese participants with type 2 diabetes (T2D) was also included. In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.
RESULTS Of 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %. Estimated treatment differences also favored both semaglutide doses versus placebo. Significant treatment-by-subgroup interactions were observed for sex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively). Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).
CONCLUSIONS Semaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population.
Copyright © 2025. Published by Elsevier Ltd.
Keywords
Clinical characteristicsGLP-1ObesityType 2 diabetesWeight management
Conflict of interest statement
Declaration of Competing Interest TK reports honoraria for lectures from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., FUJIFILM Toyama Chemical Co., Ltd., Kowa Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.; research grant funding from Asahi Mutual Life Insurance Company, Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; and advisory board consulting fees from Abbott Japan LLC., Medtronic Japan Co., Ltd., and Novo Nordisk Pharma Ltd. SYL reports honoraria for lectures from Novo Nordisk. WO has received lecture fees from Abbott Japan LLC, Nippon Boehringer Ingelheim, Novo Nordisk Pharma Ltd., and Sumitomo Pharma; research funding from Abbott Diabetes Care UK Ltd., Nippon Boehringer Ingelheim, Nippon Eli Lilly Japan K.K., Noster, Novo Nordisk Pharma Ltd., Sumitomo Pharma, and Teijin Pharma; and subsidies or donations from Kowa Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Sumitomo Pharma, Takeda Pharmaceutical, and Teijin Pharma. TN is an employee and shareholder of Novo Nordisk. MO is an employee of Novo Nordisk. KT received lecture fees from Kowa Pharmaceutical Co. Ltd, MSD K.K., and Novo Nordisk Pharma Ltd., and grants from Asahi Kasei Pharma Corporation, Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Heiseikai Medical corporation association Sakurai Hospital, Japan Diabetes Foundation Kuwayamakai Medical corporation association Tanbo Hospital, Medical corporation association Shichitokukai, Medical corporation association Shikinokai, Mitsubishi Tanabe Pharma Corporation, MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., Suntory Global Innovation Center Ltd., Takeda, Pharmaceutical Co. Ltd., Teijin Pharma Limited, and The Mitsubishi Foundation. TY has received lecture fees from Abbott Japan LLC, Arkray Marketing, Inc., Astellas Pharma Inc, AstraZeneca K.K., Bayer Holding, Ltd., Boehringer Ingelheim, Cosmic Corporation, Covidien Japan Inc. (Medtronic Japan Co., Ltd.), Dojindo Laboratories, Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., FUJIFILM Toyama Chemical Co., Ltd., Kissei, Kowa Pharmaceutical Co. Ltd., Kyorin Pharmaceutical, Kyowa Kirin, LifeScan Japan, Inc., Mitsubishi Tanabe Pharma Corporation, MSD, Musashino Foods Corporation, Nippon Becton Dickinson, Novartis Pharma K.K., Novo Nordisk, Ono, Roche DC Japan, Sanofi, Sanwa Chemistry Laboratory, Sumitomo Dainippon, Taisho, Takeda, Teijin Healthcare, and Terumo; grants and endowments from Aero Switch Therapeutics, Inc., Asahi Mutual Life Insurance Company, Astellas Pharma Inc., Bayer Holding, Ltd., Daiichi Sankyo Co., Ltd., EA Pharma, Eli Lilly Japan K.K., Kowa Pharmaceutical Co. Ltd., Kyowa Kirin, Minophagen, Mitsubishi Corporation Life Sciences, Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim Co., Ltd., Nipro Corporation, Nitto Boseki Co., Ltd., Novartis Pharma K.K., Novo Nordisk, Ono, Sanofi, Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda, and Tosoh Corporation; and consulting fees from Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanofi K.K., and Viatris Pharmaceutical Japan Inc. SL is an advisory board member for AstraZeneca K.K. and Novo Nordisk Pharma Ltd.; reports honoraria for lectures from AstraZeneca K.K., Boehringer Ingelheim, MSD, Novo Nordisk Pharma Ltd., and Sanofi; and has received research funding from CKD and Eli Lilly Japan K.K.
그 밖의 정보
- 출판 형태
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- 저널
- Obesity research & clinical practice · ISSN 1871-403X
- 전자 출판
- 2025-01-16
- MeSH
- Adult · Aged · Female · Humans · Male · Middle Aged · Body Mass Index · Diabetes Mellitus, Type 2 / drug therapy / complications · Double-Blind Method · East Asian People · Glucagon-Like Peptides* / therapeutic use / administration & dosage · Hypoglycemic Agents* / therapeutic use · Japan · Obesity* / drug therapy / complications · Overweight* / drug therapy · Republic of Korea · Treatment Outcome · Weight Loss* / drug effects · Glucagon-Like Peptide 1 · Semaglutide
- Substances
- Glucagon-Like Peptides · Hypoglycemic Agents · Glucagon-Like Peptide 1 · Semaglutide